Competition?, page-2

"Experts note that research presented at meetings should be considered preliminary because it has not been subjected to the rigorous scrutiny given to research published in medical journals."

Definitely a similar target procedure, however the sample pool was very small and their work is yet to be scrutinized by peers in the field. I own RHY and am willing to back the work of CSIRO. Ultimately it comes down to when they can get the test to market and at what price for etc etc so there are a lot of variables (risk) still to check off before they get to that stage. Anyway it's got the right people in the seats that matter so hopefully they are returning sales revenue into 2019.